| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
118,790,000 |
| Market
Cap: |
42.71(M) |
| Last
Volume: |
19,275,386 |
Avg
Vol: |
8,941,637 |
| 52
Week Range: |
$0.3595 - $0.3595 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Novavax is a biotechnology company that promotes improved global health through the discovery, development and commercialization of vaccines to prevent serious infectious diseases. Co.'s vaccine candidates, including both its coronavirus vaccine candidate, NVX-CoV2373, and its primary influenza vaccine candidate, NanoFlu, are genetically engineered, three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis. NVX-CoV2373 and NanoFlu include the use of Co.'s proprietary Matrix-M™ adjuvant.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
6,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$43,042 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
3 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Glenn Gregory M |
President, R&D |
• – – |
2016-12-07 |
4 |
B |
$1.45 |
$1,446 |
D/D |
1,000 |
4,427 |
2.66 |
- |
|
| Trizzino John |
SVP, Commercial Operations |
• – – |
2016-09-22 |
4 |
B |
$2.17 |
$99,820 |
D/D |
46,000 |
85,564 |
2.74 |
- |
|
| Douglas Richard |
Director |
– • – |
2016-09-21 |
4 |
B |
$1.72 |
$172,010 |
D/D |
100,000 |
350,000 |
2.39 |
- |
|
| Glenn Gregory M |
President, R&D |
• – – |
2016-09-21 |
4 |
B |
$1.65 |
$1,649 |
D/D |
1,000 |
3,427 |
2.66 |
- |
|
| Mcmanus Michael A Jr |
Director |
– • – |
2016-09-21 |
4 |
B |
$1.61 |
$48,297 |
D/D |
30,000 |
247,590 |
2.39 |
- |
|
| Boudreaux Gail |
Director |
– • – |
2016-09-20 |
4 |
B |
$1.45 |
$144,850 |
D/D |
100,000 |
200,000 |
2.39 |
- |
|
| Phillips Barclay A |
SVP, Chief Financial Officer |
• – – |
2016-07-31 |
4 |
B |
$4.29 |
$1,810 |
D/D |
422 |
9,979 |
2.66 |
- |
|
| Evans Gray C |
Director |
– • – |
2016-06-06 |
4 |
S |
$6.50 |
$123,487 |
D/D |
(18,998) |
321,979 |
|
- |
|
| Evans Gray C |
Director |
– • – |
2016-05-24 |
4 |
S |
$5.42 |
$87,495 |
D/D |
(16,134) |
340,977 |
|
- |
|
| Evans Gray C |
Director |
– • – |
2016-05-23 |
4 |
S |
$5.40 |
$182,876 |
D/D |
(33,866) |
357,111 |
|
- |
|
| Erck Stanley C |
President and CEO |
• • – |
2016-03-31 |
4 |
S |
$5.18 |
$1,175,616 |
D/D |
(226,769) |
78,279 |
|
- |
|
| Erck Stanley C |
President and CEO |
• • – |
2016-03-31 |
4 |
OE |
$1.28 |
$258,548 |
D/D |
201,991 |
305,048 |
|
- |
|
| Erck Stanley C |
President and CEO |
• • – |
2016-03-30 |
4 |
S |
$5.19 |
$1,028,003 |
D/D |
(198,009) |
103,057 |
|
- |
|
| Erck Stanley C |
President and CEO |
• • – |
2016-03-30 |
4 |
OE |
$1.28 |
$253,452 |
D/D |
198,009 |
301,066 |
|
- |
|
| Evans Gray C |
Director |
– • – |
2016-02-17 |
4 |
OE |
$4.60 |
$230,000 |
D/D |
50,000 |
390,977 |
|
- |
|
| Trizzino John |
SVP, Commercial Operations |
• – – |
2016-01-31 |
4 |
B |
$3.63 |
$21,254 |
D/D |
5,855 |
39,564 |
2.74 |
- |
|
| Erck Stanley C |
CEO and President |
• • – |
2016-01-31 |
4 |
B |
$4.38 |
$9,075 |
D/D |
2,072 |
103,057 |
2.81 |
- |
|
| Phillips Barclay A |
SVP, Chief Financial Officer |
• – – |
2016-01-31 |
4 |
B |
$4.38 |
$1,774 |
D/D |
405 |
9,557 |
2.66 |
- |
|
| Glenn Gregory M |
SVP, Research and Development |
• – – |
2016-01-31 |
4 |
B |
$4.38 |
$10,376 |
D/D |
2,369 |
2,427 |
2.74 |
- |
|
| Herrmann John A Iii |
SVP, General Counsel |
• – – |
2016-01-31 |
4 |
B |
$4.38 |
$9,075 |
D/D |
2,072 |
2,112 |
2.74 |
- |
|
| Glenn Gregory M |
SVP, Research and Development |
• – – |
2015-12-16 |
4 |
S |
$8.58 |
$530,697 |
D/D |
(61,886) |
58 |
|
- |
|
| Glenn Gregory M |
SVP, Research and Development |
• – – |
2015-12-16 |
4 |
OE |
$1.83 |
$113,251 |
D/D |
61,886 |
61,944 |
|
- |
|
| Herrmann John A Iii |
SVP, General Counsel |
• – – |
2015-12-16 |
4 |
S |
$8.64 |
$241,420 |
D/D |
(27,945) |
40 |
|
- |
|
| Glenn Gregory M |
SVP, Research and Development |
• – – |
2015-08-24 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,100 |
58 |
|
- |
|
| Evans Gray C |
Director |
– • – |
2015-08-24 |
4 |
S |
$11.24 |
$224,808 |
D/D |
(20,000) |
340,977 |
|
- |
|
604 Records found
|
|
Page 16 of 25 |
|
|
